To include your compound in the COVID-19 Resource Center, submit it here.

AstraZeneca, Leo Pharma deal

AstraZeneca granted Leo exclusive, worldwide rights to tralokinumab ( CAT-354) for dermatological indications and exclusive, European rights to brodalumab ( KHK4827). For tralokinumab, AZ

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE